Advertisement

International Journal of Colorectal Disease

, Volume 33, Issue 11, pp 1517–1523 | Cite as

Brain metastases in colorectal cancer: prognostic factors and survival analysis

  • Luis Del Carpio Huerta
  • Anna Cristina Virgili Manrique
  • Justyna Szafranska
  • Marta Martin-Richard
  • David Paez Lopez-Bravo
  • Ana Sebio Garcia
  • Iñigo Espinosa Mariscal
  • Paula Gomila Pons
  • Marta Andres Granyo
  • Andres Barba Joaquin
  • Agusti Barnadas Molins
  • Maria Tobeña Puyal
Original Article

Abstract

Purpose

Colorectal cancer (CRC) brain metastases (BM) are an uncommon and late event. We aim to investigate the impact of clinical factors, treatment modalities and RAS/BRAF status on the outcomes of CRC patients with BM.

Patients

We retrospectively analysed CRC patients who developed BM in our centre between January 1997 and June 2017. Clinical factors, treatment modalities, RAS/BRAF status and survival were evaluated.

Results

Twenty-eight patients were recorded; 82% had left-sided (LS) CRC and 71% had lung metastases. Median time to BM diagnosis was 36 months (m) and 93% of patients received local treatment of BM (43% whole brain radiotherapy, 50% surgery). Right-sided (RS) CRC showed shorter time to BM, not previously described (9.3 vs 46.6 m for RS and LS CRC, respectively; HR = 4.7, p = 0.006). Median overall survival (mOS) from BM treatment was 9.5 m, better in patients who underwent surgery than those treated with radiotherapy alone (12.1 vs 4.6 m, respectively; HR = 0.3, p = 0.019) and in those without progressive metastatic extracranial disease (7.2 vs 20.9 m, for progressive and non-progressive, respectively; HR = 0.3, p = 0.056). Patients with two or more metastatic extracranial locations showed worse prognosis (5.9 vs 16.3 m, for > 2 vs 0–1, respectively; HR = 3.7, p = 0.015). RAS/BRAF status did not showed prognostic value.

Conclusions

Time to BM diagnosis is shorter in RS CRC. The presence of two or more metastatic extracranial locations and progressive metastatic extracranial disease at the time of BM diagnosis could be bad prognosis factors for CRC BM patients.

Keywords

Colorectal cancer Brain metastases Colorectal cancer location Whole brain radiotherapy Surgery 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30.  https://doi.org/10.3322/caac.21387 CrossRefGoogle Scholar
  2. 2.
    Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM (2011) Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res 30:10.  https://doi.org/10.1186/1756-9966-30-10 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, Sen CA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E (2014) The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol 31:152.  https://doi.org/10.1007/s12032-014-0152-z CrossRefPubMedGoogle Scholar
  4. 4.
    Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH (2008) Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer 113:158–165.  https://doi.org/10.1002/cncr.23531 CrossRefPubMedGoogle Scholar
  5. 5.
    Fountzilas C, Chang K, Hernandez B, Michalek J, Crownover R, Floyd J, Mahalingam D (2017) Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience. J Gastrointest Oncol 8:55–63.  https://doi.org/10.21037/jgo.2016.12.11 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Noura S, Ohue M, Shingai T, Fujiwara A, Imada S, Sueda T, Yamada T, Fujiwara Y, Ohigashi H, Yano M, Ishikawa O (2012) Brain metastasis from colorectal cancer: prognostic factors and survival. J Surg Oncol 106:144–148.  https://doi.org/10.1002/jso.23055 CrossRefPubMedGoogle Scholar
  7. 7.
    Tevlin R, Larkin JO, Hyland JM, O’Connell PR, Winter DC (2015) Brain metastasis from colorectal carcinoma: a single cancer centre experience. Ir J Med Sci 184:673–675.  https://doi.org/10.1007/s11845-015-1272-y CrossRefPubMedGoogle Scholar
  8. 8.
    Suzuki Y, Yamaguchi T, Matsumoto H, Nakano D, Honda G, Shinoura N, Karasawa K, Takahashi K (2014) Prognostic factors and treatment effects in patients with curatively resected brain metastasis from colorectal cancer. Dis Colon Rectum 57:56–63.  https://doi.org/10.1097/01.dcr.0000436998.30504.98 CrossRefGoogle Scholar
  9. 9.
    Michl M, Thurmaier J, Schubert-Fritschle G, Wiedemann M, Laubender RP, Nüssler NC, Ruppert R, Kleeff J, Schepp W, Reuter C, Löhe F, Karthaus M, Neumann J, Kirchner T, Engel J, Heinemann V (2015) Brain metastasis in colorectal cancer patients: survival and analysis of prognostic factors. Clin Colorectal Cancer 14:281–290.  https://doi.org/10.1016/j.clcc.2015.05.009 CrossRefPubMedGoogle Scholar
  10. 10.
    Christensen TD, Palshof JA, Larsen FO, Høgdall E, Poulsen TS, Pfeiffer P, Jensen BV, Yilmaz MK, Christensen IJ, Nielsen D (2017) Risk factors for brain metastases in patients with metastatic colorectal cancer. Acta Oncol 56:639–645.  https://doi.org/10.1080/0284186X.2017.1290272 CrossRefPubMedGoogle Scholar
  11. 11.
    Tokoro T, Okuno K, Hida JC, Ueda K, Yoshifuji T, Daito K, Sugiura F (2014) Prognostic factors for patients with advanced colorectal cancer and symptomatic brain metastases. Clin Color Cancer 13:226–231.  https://doi.org/10.1016/j.clcc.2014.09.008 CrossRefGoogle Scholar
  12. 12.
    Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N (2015) RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121:1195–1203.  https://doi.org/10.1002/cncr.29196 CrossRefPubMedGoogle Scholar
  13. 13.
    Gaspar L, Scott C, Rotman M et al (1997) Analysis ( Rpa ) of prognostic factors therapy oncology group ( Rtog ) trials. Radiat Oncol 37:745–751Google Scholar
  14. 14.
    Silva IL, Iskandarani M, Hotouras A, Murphy J, Bhan C, Adada B, Wexner SD (2017) A systematic review to assess the management of patients with cerebral metastases secondary to colorectal cancer. Tech Coloproctol 21:847–852.  https://doi.org/10.1007/s10151-017-1707-8 CrossRefPubMedGoogle Scholar
  15. 15.
    Tong JHM, Lung RWM, Sin FMC, Law PPY, Kang W, Chan AWH, Ma BBY, Mak TWC, Ng SSM, To KF (2014) Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther 15:768–776.  https://doi.org/10.4161/cbt.28550 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Missiaglia E, Jacobs B, D’Ario G et al (2014) Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25:1995–2001.  https://doi.org/10.1093/annonc/mdu275 CrossRefPubMedGoogle Scholar
  17. 17.
    Gao XH, Yu GY, Gong HF, Liu LJ, Xu Y, Hao LQ, Liu P, Liu ZH, Bai CG, Zhang W (2017) Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Sci Rep 7:7882.  https://doi.org/10.1038/s41598-017-08413-z CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Stintzing S, Tejpar S, Gibbs P, Thiebach L (2017) Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer 84:69–80.  https://doi.org/10.1016/j.ejca.2017.07.016 CrossRefPubMedGoogle Scholar
  19. 19.
    Hussain M, Waqas O, Hassan U et al (2016) Right-sided and left-sided colon cancers are two distinct disease entities: an analysis of 200 cases in Pakistan. Asian Pacific J Cancer Prev 17:2545–2548.  https://doi.org/10.7314/APJCP.2016.17.4.2545 CrossRefGoogle Scholar
  20. 20.
    Fausto Petrelli MD, Gianluca Tomasello MD, Karen Borgonovo MD, Michele Ghidini MD, Luca Turati MD, PierpaoloDallera MD, Rodolfo Passalacqua MD, Giovanni Sgroi MD, Sandro Barni M (2016) Prognostic survival associated with left-sided vs right-sided Colon Cancer a systematic review and meta-analysis. Jama Oncol 3:1–9.  https://doi.org/10.1001/jamaoncol.2016.4227 CrossRefGoogle Scholar
  21. 21.
    Magni E, Santoro L, Ravenda PS, Leonardi MC, Bonomo G, Monfardini L, Nolè F, Zampino MG (2014) Brain metastases from colorectal cancer: main clinical factors conditioning outcome. Int J Color Dis 29:201–208.  https://doi.org/10.1007/s00384-013-1781-y CrossRefGoogle Scholar
  22. 22.
    Lin L, Zhao C-H, Ge F-J, Wang Y, Chen YL, Liu RR, Jia R, Liu LJ, Liu JZ, Xu JM (2016) Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors. Clin Transl Oncol 18:93–98.  https://doi.org/10.1007/s12094-015-1341-8 CrossRefPubMedGoogle Scholar
  23. 23.
    Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, Tosteson TD, Pipas JM (2009) Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Color Cancer 8:100–105.  https://doi.org/10.3816/CCC.2009.n.016 CrossRefGoogle Scholar
  24. 24.
    Nozawa H, Ishihara S, Kawai K, Sasaki K, Murono K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Watanabe T (2017) Brain metastasis from colorectal cancer: predictors and treatment outcomes. Oncology 93:309–314.  https://doi.org/10.1159/000478661 CrossRefPubMedGoogle Scholar
  25. 25.
    Aprile G, Casagrande M, De Maglio G et al (2017) Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol 13(2):135–144.  https://doi.org/10.2217/fon-2016-0196 CrossRefPubMedGoogle Scholar
  26. 26.
    Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY (2011) Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neuro-Oncol 101:49–55.  https://doi.org/10.1007/s11060-010-0214-9 CrossRefGoogle Scholar
  27. 27.
    Nieder C, Hintz M, Grosu AL (2016) Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome. Clin Transl Oncol 18:88–92.  https://doi.org/10.1007/s12094-015-1340-9 CrossRefPubMedGoogle Scholar
  28. 28.
    Mege D, Sans A, Ouaissi M, Iannelli A, Sielezneff I (2017) Brain metastases from colorectal cancer: characteristics and management. ANZ J Surg 88:140–145.  https://doi.org/10.1111/ans.14107 CrossRefPubMedGoogle Scholar
  29. 29.
    Kased N, Binder DK, McDermott MW et al (2009) Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 75:1132–1140.  https://doi.org/10.1016/j.ijrobp.2008.12.031 CrossRefPubMedGoogle Scholar
  30. 30.
    Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, Chea M, Valéry CA, Simon JM, Mazeron JJ (2014) Stereotactic radiotherapy for large solitary brain metastases. Cancer/Radiotherapie 18:97–106.  https://doi.org/10.1016/j.canrad.2013.12.003 CrossRefGoogle Scholar
  31. 31.
    Vatandoust S, Price TJ, Karapetis CS (2015) Colorectal cancer: metastases to a single organ. World J Gastroenterol 21:11767–11776.  https://doi.org/10.3748/wjg.v21.i41.11767 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Luis Del Carpio Huerta
    • 1
  • Anna Cristina Virgili Manrique
    • 1
  • Justyna Szafranska
    • 2
  • Marta Martin-Richard
    • 1
  • David Paez Lopez-Bravo
    • 1
  • Ana Sebio Garcia
    • 1
  • Iñigo Espinosa Mariscal
    • 2
  • Paula Gomila Pons
    • 1
  • Marta Andres Granyo
    • 1
  • Andres Barba Joaquin
    • 1
  • Agusti Barnadas Molins
    • 1
  • Maria Tobeña Puyal
    • 1
  1. 1.Medical Oncology DepartmentSanta Creu i Sant Pau HospitalBarcelonaSpain
  2. 2.Pathology DepartmentSanta Creu i Sant Pau HospitalBarcelonaSpain

Personalised recommendations